References
- Audia S, Mahévas M, Samson M, Godeau B, Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmun Rev 2017;16(6):620–632. doi:https://doi.org/10.1016/j.autrev.2017.04.012.
- Neunert C, Lim W, Crowther M. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117(16):4190–4207. doi:https://doi.org/10.1182/blood-2010-08-302984.
- Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, González-López TJ, Grainger J, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115(2):168–186. doi:https://doi.org/10.1182/blood-2009-06-225565.
- Chang T, De Alwis JS, Samarasekara N, Rajapakse S. Cerebral infarction 3 weeks after intravenous immunoglobulin for Miller Fisher syndrome: A case report. J Med Case Rep 2014;8(1):2–8. doi:https://doi.org/10.1186/1752-1947-8-100.
- Mithoowani S, Gregory-Miller K, Goy J, Miller MC, Wang G, Noroozi N, Kelton JG, Arnold DM. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol 2016;3(10):e489–e496. doi:https://doi.org/10.1016/S2352-3026(16)30109-0.
- Godeau B, Lesage S, Divine M, Wirquin V, Farcet JP, Bierling P. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 1993;82(5):1415–1421.
- Godeau B, Caulier M-T, Decuypere L, Rose C, Schaeffer A, Bierling P. Intravenous immunoglobulin for adults with autoimmune thrombocytopenic purpura: results of a randomized trial comparing 0.5 and 1 g/kg b.w. Br J Haematol 1999;107(4):716–719. doi:https://doi.org/10.1046/j.1365-2141.1999.01766.x.
- Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood 2013;121(23):4782LP- 4790.
- Grace RF, Neunert C. Second-line therapies in immune thrombocytopenia. ASH Educ Progr B 2016;2016(1):698–706. doi:https://doi.org/10.1182/asheducation-2016.1.698.
- Wong RSM, Saleh MN, Khelif A, Salama A, Portella MSO, Burgess P, Bussel JB. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood 2017;130(23):2527-2536. doi: https://doi.org/10.1182/blood-2017-04-748707.
- Visco C, Rodeghiero F. Immune thrombocytopenia in lymphoproliferative disorders. Hematol Oncol Clin North Am 2009;23(6):1261–1274. doi:https://doi.org/10.1016/j.hoc.2009.08.006.
- Krauth MT, Puthenparambil J, Lechner K. Paraneoplastic autoimmune thrombocytopenia in solid tumors. Crit Rev Oncol Hematol 2012;81(1):75–81. doi:https://doi.org/10.1016/j.critrevonc.2011.02.004.
- Maverakis E, Goodarzi H, Wehrli LN, Ono Y, Garcia MS. The etiology of paraneoplastic autoimmunity. Clin Rev Allergy Immunol 2012;42(2):135–144. doi:https://doi.org/10.1007/s12016-010-8248-5.
- Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, Cuker A, Despotovic JM, George JN, Grace RF, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866. doi: https://doi.org/10.1182/bloodadvances.2019001380.
- Lakshmanan S, Cuker A. Contemporary management of primary immune thrombocytopenia in adults. J Thromb Haemost 2012;10(10):1988–1998. doi:https://doi.org/10.1111/j.1538-7836.2012.04876.x.
- Godeau B, Chevret S, Varet B, Lefrère F, Zini JM, Bassompierre F, Chèze S, Legouffe E, Hulin C, Grange MJ, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: A randomised, multicentre trial. Lancet 2002;359(9300):23–29. doi:https://doi.org/10.1016/S0140-6736(02)07275-6.
- Visco C, Barcellini W, Maura F, Neri A, Cortelezzi A, Rodeghiero F. Autoimmune cytopenias in chronic lymphocytic leukemia. Am J Hematol 2014;89(11):1055–1062. doi:https://doi.org/10.1002/ajh.23785.
- Hodgson K, Ferrer G, Montserrat E, Moreno C. Chronic lymphocytic leukemia and autoimmunity: A systematic review. Haematologica 2011;96(5):752–761. doi:https://doi.org/10.3324/haematol.2010.036152.
- Portielje JEA, Westendorp RGJ, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97(9):2549–2554. doi:https://doi.org/10.1182/blood.V97.9.2549.
- Rodeghiero F, Ruggeri M. Short- and long-term risks of splenectomy for benign haematological disorders: should we revisit the indications? Br J Haematol 2012;158(1):16–29. doi:https://doi.org/10.1111/j.1365-2141.2012.09146.x.
- Gonzalez-Porras JR, Escalante F, Pardal E, Sierra M, Garcia-Frade LJ, Redondo S, Arefi M, Aguilar C, Ortega F, de Cabo E, et al. Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia. Eur J Haematol 2013;91(3):236–241. doi:https://doi.org/10.1111/ejh.12146.
- Park YH, Yi HG, Kim CS, Hong J, Park J, Lee JH, Kim HY, Kim HJ, Zang DY, Kim SH, et al. Clinical outcome and predictive factors in the response to splenectomy in elderly patients with primary immune thrombocytopenia: A multicenter retrospective study. Acta Haematol 2016;135(3):162–171. doi:https://doi.org/10.1159/000442703.
- Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: A systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004;104(9):2623–2634. doi:https://doi.org/10.1182/blood-2004-03-1168.
- González-López TJ, Alvarez-Román MT, Pascual C, Sánchez-González B, Fernández-Fuentes F, Pérez-Rus G, Hernández-Rivas JA, Bernat S, Bastida JM, Martínez-Badas MP, et al. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice. Br J Haematol 2017;178(6):959–970. doi:https://doi.org/10.1111/bjh.14788.
- Paul S, Jain N, Ferrajoli A, O'Brien S, Burger J, Keating M, Wierda W. A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. Br J Haematol 2019;185(3):606–608. doi:https://doi.org/10.1111/bjh.15581.
- Visco C, Rodeghiero F, Romano A, Valeri F, Merli M, Quaresimini G, Volpetti S, Santi RM, Carli G, Lucchini E, et al. Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: A phase 2 multicenter study. Blood 2019;134(20):1708–1711. doi:https://doi.org/10.1182/blood.2019001617.
- Birocchi S, Podda GM, Manzoni M, Casazza G, Cattaneo M. Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review. Platelets April 2020: 1–11. doi:https://doi.org/10.1080/09537104.2020.1745168.
- Abrahamson PE, Hall SA, Feudjo-Tepie M, Mitrani-Gold FS, Logie J. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol 2009;83(2):83–89. doi:https://doi.org/10.1111/j.1600-0609.2009.01247.x.
- Schoonen WM, Kucera G, Coalson J, Li L, Rutstein M, Mowat F, Fryzek J, Kaye JA. Epidemiology of immune thrombocytopenic purpura in the general practice research database. Br J Haematol 2009;145(2):235–244. doi:https://doi.org/10.1111/j.1365-2141.2009.07615.x.
- Neylon AJ, Saunders PWG, Howard MR, Proctor SJ, Taylor PRA. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: A prospective study of a population-based cohort of 245 patients. Br J Haematol 2003;122(6):966–974. doi:https://doi.org/10.1046/j.1365-2141.2003.04547.x.
- Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol 2010;85(3):NA–NA. doi:https://doi.org/10.1002/ajh.21616.
- Podda GM, Ricci S. Platelet transfusion strategy for hematologic cancers. Intern Emerg Med 2014;10:1. doi:https://doi.org/10.1007/s11739-014-1148-6.
- Johnstone C, Rich SE. Bleeding in cancer patients and its treatment: a review. Ann Palliat Med 2018;7(2):265–273. doi:https://doi.org/10.21037/apm.2017.11.01.
- Prandoni P, Lensing AW, Buller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327(16):1128–1133. doi:https://doi.org/10.1056/NEJM199210153271604.